Physiomics plc (AIM: PYC), a mathematical modelling, data science and biostatistics company, announced on Wednesday that it has been awarded a new contract by long-standing client Numab Therapeutics AG to support clinical dose selection for a First In Human study in its inflammation pipeline.

The project will apply PK/PD modelling and simulation to guide early-stage dosing decisions, with work set to begin imminently and complete within six months.

This engagement marks a continued application of Model Informed Drug Development strategies within the collaboration, reinforcing Physiomics' role in advancing data-driven approaches to therapeutic development.